Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
HealthPartners Institute
With
University of Minnesota
University of Southern California
This project will determine the efficacy of vitamin D3 supplements for reducing side effects of treatment with aromatase inhibitors in women with a history of breast cancer that have no evidence of current disease. The aromatase inhibitors (AI) have become a critical component of adjuvant therapy for this population, but they cause bone pain, joint pain, joint stiffness, and muscle weakness in approximately 40% of patients. These symptoms, referred to as aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), decrease quality of life and medication adherence. Identifying effective ways to decrease these symptoms may allow for longer and more adherent medication use and thus may improve disease-free survival. We hypothesize that vitamin D3 may decrease symptoms associated with the use of aromatase inhibitors.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Women with a history of stage I-IIIa invasive breast cancer
History of hormone-receptor positive cancer (either ER + or PR + or both)
Are prescribed and are taking anastrozole, letrozole or exemestane for at least one month and have at least 7 months of AI treatment remaining
Are experiencing AIMSS
You may not be if
Unable to read or understand English
History of psychiatric disability affecting informed consent or compliance with drug intake
Malabsorption syndrome or inability to take oral medication